Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015248 | 0.89 | L3MBTL1 (0.55) | L3MBTL1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL8553183 | 0.84 | ADORA2A (0.48) | ADORA3ADORA2AADORA1SMN1; SMN2NPC1 | |
| SCHEMBL31632979 | 0.80 | KDM4C (0.50) | L3MBTL1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1014119 | 0.79 | KMT2A (0.56) | L3MBTL1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL31661440 | 0.78 | ALDH1A1 (0.43) | L3MBTL1SMN1; SMN2MAPTTSHRHTT | |
| SCHEMBL1095617 | 0.78 | L3MBTL1 (0.48) | L3MBTL1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL31661655 | 0.77 | KDM4C (0.41) | ADORA3ADORA2AADORA1SMN1; SMN2MAPT | |
| SCHEMBL31632791 | 0.76 | MRGPRX4 (0.46) | L3MBTL1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL30585031 | 0.75 | KMT2A (0.50) | ADORA3ADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL20360015 | 0.74 | NPC1 (0.37) | L3MBTL1ADORA3SMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744446-A | Hetero-aromatic compound and application thereof in medicine | GUANGDONG HEC PHARMACEUTICAL | 2015-07-01 | — | — | CN | disclosed |
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1802633-B1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| EP-2001890-B1 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND USE FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-7750017-B2 | Heterocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20080132497-A1 | Novel Heterocycles | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1802633-A1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044524-A1 | BENZOTHIENO’2,3-D! PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | DPYD, TYMP, TPMT | L3MBTL1 3837/4885ADORA3 765/4885ADORA2A 770/4885 |
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | L3MBTL1 4676/4885ADORA3 4494/4885ADORA2A 3195/4885 |
| US-20080132497-A1 | Novel Heterocycles | HRAS, CCNC, PCNA | L3MBTL1 3934/4885ADORA3 4428/4885ADORA2A 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.